SCHEMBL2388992

SCHEMBL2388992

Cc1ccn(C(c2ccccc2)(c2ccccc2)c2ccccc2Cl)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 3/20 0.60
KCNA3 P22001 2/20 0.60
SMN1; SMN2 Q16637 4/20 0.51
OPRK1 P41145 3/20 0.51
KCNH2 Q12809 3/20 0.51
RAB9A P51151 3/20 0.51
HTR2A P28223 2/20 0.51
HTR2C P28335 2/20 0.51
NR1I2 O75469 2/20 0.51
ADORA3 P0DMS8 2/20 0.51
TBXA2R P21731 2/20 0.51
CCKBR P32239 2/20 0.51
SLC6A3 Q01959 2/20 0.51
NR1H4 Q96RI1 2/20 0.51
HTT P42858 2/20 0.51
CYP3A4 P08684 2/20 0.51
TSHR P16473 2/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14478094 0.84 CYP11B1 (0.40) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2
SCHEMBL16965405 0.81 KCNN4 (0.56) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2
SCHEMBL14896416 0.81 KCNN4 (0.56) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2
SCHEMBL12264160 0.79 KCNN4 (0.57) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2
SCHEMBL16965063 0.77 KCNN4 (0.51) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2
SCHEMBL41130 0.75 KCNN4 (1.00) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2
SCHEMBL29499525 0.75 KCNN4 (1.00) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2
SCHEMBL16965740 0.75 KCNN4 (0.58) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2
SCHEMBL332282 0.75 KCNN4 (0.48) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2
SCHEMBL7789691 0.74 KCNN4 (0.66) KCNN4KCNA3SMN1; SMN2OPRK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026263-B2 Methods for inhibiting neoproliferative changes in blood vessel walls THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-09-27 US disclosed
US-8026263-B2 Methods for inhibiting neoproliferative changes in blood vessel walls THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-09-27 US disclosed
US-8026263-B2 Methods for inhibiting neoproliferative changes in blood vessel walls THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-09-27 US disclosed
US-20090048270-A1 Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-02-19 US disclosed
US-7235577-B1 Non-peptide inhibition of T-lymphocyte activation and therapies related thereto THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-06-26 US disclosed
US-7235577-B1 Non-peptide inhibition of T-lymphocyte activation and therapies related thereto THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048270-A1 Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls PGF, VEGFA, MKI67 KCNN4 4235/4885KCNA3 4627/4885SMN1; SMN2 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.